Odonate Therapeutics, Inc. (ODTC) financial statements (2022 and earlier)

Company profile

Business Address 3 EAST 28TH STREET
NEW YORK, NY 10016
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

9/30/2021
TTM
12/31/2020
12/31/2019
12/31/2018
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments 157,265180,460139,050
Cash and cash equivalents 157,265180,460139,050
Prepaid expense   750
Other undisclosed current assets 2,6073,468 
Total current assets: 159,872183,928139,800
Noncurrent Assets
Operating lease, right-of-use asset 4,0171,581
Property, plant and equipment 2,2861,6631,899
Restricted cash and investments 714714251
Other noncurrent assets 997941723
Total noncurrent assets: 8,0144,8992,873
TOTAL ASSETS: 167,886188,827142,673
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities 26,41524,46418,142
Accounts payable 14,16815,58310,777
Accrued liabilities 12,2478,8817,365
Debt  315 
Deferred rent credit   66
Other undisclosed current liabilities 658  
Total current liabilities: 27,07324,77918,208
Noncurrent Liabilities
Long-term debt and lease obligation 4,6681,748 
Operating lease, liability 4,6681,748
Liabilities, other than long-term debt   461
Deferred rent credit   461
Other undisclosed noncurrent liabilities (4,668)  
Total noncurrent liabilities: 4,6681,748461
Total liabilities: 31,74126,52718,669
Stockholders' equity
Stockholders' equity attributable to parent 136,145162,300124,004
Common stock 367300244
Additional paid in capital 502,205402,077252,012
Accumulated deficit (366,427)(240,077)(128,252)
Total stockholders' equity: 136,145162,300124,004
TOTAL LIABILITIES AND EQUITY: 167,886188,827142,673

Income statement (P&L) ($ in thousands)

9/30/2021
TTM
12/31/2020
12/31/2019
12/31/2018
Operating expenses (127,433)(114,930)(90,764)
Operating loss: (127,433)(114,930)(90,764)
Nonoperating income
(Other Nonoperating income)
 1,083  
Loss before gain (loss) on sale of properties: (126,350)(114,930)(90,764)
Other undisclosed net income  3,1051,804
Net loss available to common stockholders, diluted: (126,350)(111,825)(88,960)

Comprehensive Income ($ in thousands)

9/30/2021
TTM
12/31/2020
12/31/2019
12/31/2018
Net loss: (126,350)(111,825)(88,960)
Comprehensive loss, net of tax, attributable to parent: (126,350)(111,825)(88,960)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: